Aromatization

Aromatase (CYP19A1) is a cytochrome P450 enzyme expressed primarily in adipose tissue, the central nervous system, and bone. It catalyses the conversion of C19 androgens into C18 estrogens via three sequential hydroxylation steps, the third of which cleaves the 19-methyl group and aromatises the A-ring — hence the name.

Substrate-product pairs:

– Testosterone → estradiol (E2), the clinically dominant conversion
– Androstenedione → estrone (E1), converted back to E2 in peripheral tissues
– Methandrostenolone → 17α-methylestradiol, distinct from native E2 and resistant to AI blockade

Conversion rate at physiological serum testosterone: approximately 0.2–0.3% of substrate is aromatised. Higher adipose mass drives higher absolute conversion — obese subjects reliably show elevated E2 at identical testosterone doses.

Compounds that aromatise:

– Testosterone (every ester, all routes) — the reference substrate
– Methandrostenolone (Dianabol) — produces methylestradiol; anastrozole is pharmacologically ineffective against methyl-estradiol, SERM-based gyno control is the better tool
– Boldenone — roughly half the rate of testosterone per mg

Compounds that do not aromatise:

– DHT-derivatives: stanozolol, oxandrolone, drostanolone — A-ring modifications block CYP19A1 substrate recognition entirely
– Trenbolone — non-aromatizable but agonist at the progesterone receptor; the clinical symptom profile overlaps with estrogenic effects (water retention, gyno risk), driven by PR not ER activation
– Nandrolone — minimal aromatisation (~20% of testosterone rate), but produces estrogenic-like effects via a separate mechanism requiring targeted SERM intervention

Target serum E2 on protocol: 25–40 pg/mL on sensitive LC-MS/MS assay (not standard immunoassay, which overestimates low values in males). The error pattern clinicians see most often is iatrogenic hypoestrogenaemia from aggressive AI dosing — E2 crashed below 20 pg/mL produces the documented syndrome of arthralgia, cognitive dulling, libido loss, lipid degradation, and sleep disturbance, which users routinely misattribute to the AAS itself or to something else going on.

Aromatase inhibitors (anastrozole, letrozole, exemestane) block the enzyme directly; SERMs (tamoxifen, raloxifene) block the estrogen receptor at target tissue. AI suppresses systemic E2; SERM prevents ER activation locally without affecting serum values. For gynecomastia prophylaxis, SERM is often sufficient; for systemic estrogenic symptoms (water retention, mood), AI is the tool — but only titrated to measured bloodwork values, never preemptively.